Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 14, 2020

Edwards Lifesciences and Abbott to settle transcatheter litigation

Edwards Lifesciences has reached an agreement with Abbott to settle all outstanding patent disputes in cases related to transcatheter mitral and tricuspid repair products.

Edwards Lifesciences has reached an agreement with Abbott to settle all outstanding patent disputes in cases related to transcatheter mitral and tricuspid repair products.

As part of the agreement, the companies will withdraw all pending cases or appeals in courts and patent offices worldwide.

The companies caught up in legal dispute for over a year after Abbott sued Edwards for patent infringement over its MitraClip. The companies had lawsuits pending in several jurisdictions globally.

The agreement specifies that both parties will not litigate patent disputes with each other in the field of transcatheter mitral and tricuspid repair and replacement products for the ten-year duration of the agreement.

In connection with the agreement, any injunctions that are currently in place will also be lifted.

Abbott said it will receive a one-time payment and ongoing payments based on Pascal sales through 2025, as well as a potential sales milestone payment in 2026.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

Meanwhile, Edwards will book a one-time settlement expense in the June-ending quarter and will pay royalties to Abbott until May 2024. In addition, the company will incur royalty expenses until May 2024.

Edwards said it considers the agreement as a positive development as it allows the company to fully dedicate time and resources to help patients.

The companies have not disclosed the details of the settlement.

Last month, Abbot reported late-breaking data on its MitraClip system for transcatheter mitral valve repair and data on TriClip system for transcatheter tricuspid valve repair and the Tendyne transcatheter mitral valve implantation system.

The company received the US Food and Drug Administration (FDA) approval for its Gallant implantable cardioverter-defibrillator (ICD) and cardiac resynchronisation therapy defibrillator (CRT-D) devices last week.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU